Skip to main content

Home-Based Testing Firm EverlyWell Raises $50M

NEW YORK (360Dx) – Home-based testing firm EverlyWell today announced it had raised $50 million to expand its digital platform and scale existing partnerships with companies including CVS and Humana.

The financing was led by existing investor Goodwater Capital. Highland Capital Partners also participated in the financing.

In a statement, the Austin, Texas-based company, which was founded in 2015, said that its mission is to provide consumers access to laboratory tests. While traditional testing is "cumbersome, costly, and confusing," EverlyWell's digital platform connects consumers with CLIA-certified labs for home-based collection tests ordered and reviewed by board-certified physicians. After a sample is provided by the patient, online results, suggestions, and next steps are returned in a few days, the firm said.

The more-than-30 tests currently offered by EverlyWell include those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid. Prices start at $49.

According to the company's website, its medical team "curates" the most appropriate biomarkers for each test, whose results a patient can share with a doctor. Except for its STD tests, EverlyWell's tests are not intended as diagnostic tests, the company noted, and patients are advised to seek physician advice for proper medical care.

"We’re building the definitive technology-enabled healthcare platform that consumers deserve and have already come to expect in other areas of their lives," EverlyWell Founder and CEO Julia Cheek said in a statement.

The company also announced today that MIT professor Robert Langer has been appointed the head of its scientific board.